Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Multiple sclerosis (relapsing-remitting) - alemtuzumab: evaluation report:

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Genzyme (response to ACD)

03. Consultee comments on the ACD - Genzyme (additional information)

04. Consultee comments on the ACD - Genzyme (Appendix 1)

05. Consultee comments on the ACD - Genzyme (Appendix 2)

06. Consultee comments on the ACD - Genzyme (Appendix 3)

07. Consultee comments on the ACD - Genzyme (Appendix 4)

08. Consultee comments on the ACD - Multiple Sclerosis Society

09. Consultee comments on the ACD - Multiple Sclerosis Trust and United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA)

10. Consultee comments on the ACD - Shift MS

11. Consultee comments on the ACD - Association of British Neurologists

12. Consultee comments on the ACD - Royal College of Nursing

13. Consultee comments on the ACD - Royal College of Pathologists

14. Consultee comments on the ACD - Department of Health

15. Commentator comments on the ACD - Biogen

16. Commentator comments on the ACD - Novartis

17. Clinical expert comments on the ACD - COLES

18. Patient expert comments on the ACD - BURCHMORE

19. Public comments on the ACD received via the NICE website

20. ERG overview of manufacturer's response to the ACD

21. ERG overview of manufacturer's additional analysis in response to the data requests made in the ACD

22. ERG additional analyses

23. ERG additional analyses 2

If you have difficulties viewing this document, you may have to save to your device and open.